Lipoprotein(a) mass: a massively misunderstood metric

Joseph P. McConnell, Philip A. Guadagno, Thomas D. Dayspring, Daniel M. Hoefner, Dawn L. Thiselton, G. Russell Warnick, William Harris

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The importance of lipoprotein (a)-Lp(a)-as a cardiovascular (CV) risk marker has been underscored by recent findings that CV risk is directly related to baseline Lp(a) levels, even in well-treated patients. Although there is currently little that can be done pharmacologically to lower Lp(a) levels, knowledge of its serum concentration is important in overall risk assessment. This review focuses on 1 aspect of Lp(a) that is rarely discussed directly: how to express its levels in serum. There is considerable confusion on this point, and a fuller understanding of what the concentration units mean will help improve study-to-study comparisons and thereby advance our understanding of the pathobiology of this lipoprotein particle. As discussed here, the term Lp(a) mass refers to the entire mass of the particle: lipids, proteins, and carbohydrates combined. At present, there are no commercially available assays that are completely insensitive to the variability in particle mass, which arises not only from differences in apo(a) isoform mass but also from variations in lipid mass. Because lipoprotein "particle number" (molar concentration) has been found to be superior to component-based metrics (ie, low-density lipoprotein particle vs cholesterol concentrations) for CV disease risk prediction, the development of a mass-insensitive Lp(a) assay should be a high priority.

Original languageEnglish (US)
Pages (from-to)550-553
Number of pages4
JournalJournal of Clinical Lipidology
Volume8
Issue number6
DOIs
StatePublished - Nov 1 2014
Externally publishedYes

Fingerprint

Lipoprotein(a)
Lipoproteins
Lipids
Serum
LDL Lipoproteins
Protein Isoforms
Cardiovascular Diseases
Cholesterol
Carbohydrates
Proteins

Keywords

  • Apolipoprotein(a)
  • Laboratory methods
  • Lipoprotein(a)
  • Lipoproteins
  • Particle number

ASJC Scopus subject areas

  • Medicine(all)

Cite this

McConnell, J. P., Guadagno, P. A., Dayspring, T. D., Hoefner, D. M., Thiselton, D. L., Warnick, G. R., & Harris, W. (2014). Lipoprotein(a) mass: a massively misunderstood metric. Journal of Clinical Lipidology, 8(6), 550-553. https://doi.org/10.1016/j.jacl.2014.08.003

Lipoprotein(a) mass : a massively misunderstood metric. / McConnell, Joseph P.; Guadagno, Philip A.; Dayspring, Thomas D.; Hoefner, Daniel M.; Thiselton, Dawn L.; Warnick, G. Russell; Harris, William.

In: Journal of Clinical Lipidology, Vol. 8, No. 6, 01.11.2014, p. 550-553.

Research output: Contribution to journalArticle

McConnell, JP, Guadagno, PA, Dayspring, TD, Hoefner, DM, Thiselton, DL, Warnick, GR & Harris, W 2014, 'Lipoprotein(a) mass: a massively misunderstood metric', Journal of Clinical Lipidology, vol. 8, no. 6, pp. 550-553. https://doi.org/10.1016/j.jacl.2014.08.003
McConnell JP, Guadagno PA, Dayspring TD, Hoefner DM, Thiselton DL, Warnick GR et al. Lipoprotein(a) mass: a massively misunderstood metric. Journal of Clinical Lipidology. 2014 Nov 1;8(6):550-553. https://doi.org/10.1016/j.jacl.2014.08.003
McConnell, Joseph P. ; Guadagno, Philip A. ; Dayspring, Thomas D. ; Hoefner, Daniel M. ; Thiselton, Dawn L. ; Warnick, G. Russell ; Harris, William. / Lipoprotein(a) mass : a massively misunderstood metric. In: Journal of Clinical Lipidology. 2014 ; Vol. 8, No. 6. pp. 550-553.
@article{7f7de5d968f141148addbb622a24ab47,
title = "Lipoprotein(a) mass: a massively misunderstood metric",
abstract = "The importance of lipoprotein (a)-Lp(a)-as a cardiovascular (CV) risk marker has been underscored by recent findings that CV risk is directly related to baseline Lp(a) levels, even in well-treated patients. Although there is currently little that can be done pharmacologically to lower Lp(a) levels, knowledge of its serum concentration is important in overall risk assessment. This review focuses on 1 aspect of Lp(a) that is rarely discussed directly: how to express its levels in serum. There is considerable confusion on this point, and a fuller understanding of what the concentration units mean will help improve study-to-study comparisons and thereby advance our understanding of the pathobiology of this lipoprotein particle. As discussed here, the term Lp(a) mass refers to the entire mass of the particle: lipids, proteins, and carbohydrates combined. At present, there are no commercially available assays that are completely insensitive to the variability in particle mass, which arises not only from differences in apo(a) isoform mass but also from variations in lipid mass. Because lipoprotein {"}particle number{"} (molar concentration) has been found to be superior to component-based metrics (ie, low-density lipoprotein particle vs cholesterol concentrations) for CV disease risk prediction, the development of a mass-insensitive Lp(a) assay should be a high priority.",
keywords = "Apolipoprotein(a), Laboratory methods, Lipoprotein(a), Lipoproteins, Particle number",
author = "McConnell, {Joseph P.} and Guadagno, {Philip A.} and Dayspring, {Thomas D.} and Hoefner, {Daniel M.} and Thiselton, {Dawn L.} and Warnick, {G. Russell} and William Harris",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.jacl.2014.08.003",
language = "English (US)",
volume = "8",
pages = "550--553",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Lipoprotein(a) mass

T2 - a massively misunderstood metric

AU - McConnell, Joseph P.

AU - Guadagno, Philip A.

AU - Dayspring, Thomas D.

AU - Hoefner, Daniel M.

AU - Thiselton, Dawn L.

AU - Warnick, G. Russell

AU - Harris, William

PY - 2014/11/1

Y1 - 2014/11/1

N2 - The importance of lipoprotein (a)-Lp(a)-as a cardiovascular (CV) risk marker has been underscored by recent findings that CV risk is directly related to baseline Lp(a) levels, even in well-treated patients. Although there is currently little that can be done pharmacologically to lower Lp(a) levels, knowledge of its serum concentration is important in overall risk assessment. This review focuses on 1 aspect of Lp(a) that is rarely discussed directly: how to express its levels in serum. There is considerable confusion on this point, and a fuller understanding of what the concentration units mean will help improve study-to-study comparisons and thereby advance our understanding of the pathobiology of this lipoprotein particle. As discussed here, the term Lp(a) mass refers to the entire mass of the particle: lipids, proteins, and carbohydrates combined. At present, there are no commercially available assays that are completely insensitive to the variability in particle mass, which arises not only from differences in apo(a) isoform mass but also from variations in lipid mass. Because lipoprotein "particle number" (molar concentration) has been found to be superior to component-based metrics (ie, low-density lipoprotein particle vs cholesterol concentrations) for CV disease risk prediction, the development of a mass-insensitive Lp(a) assay should be a high priority.

AB - The importance of lipoprotein (a)-Lp(a)-as a cardiovascular (CV) risk marker has been underscored by recent findings that CV risk is directly related to baseline Lp(a) levels, even in well-treated patients. Although there is currently little that can be done pharmacologically to lower Lp(a) levels, knowledge of its serum concentration is important in overall risk assessment. This review focuses on 1 aspect of Lp(a) that is rarely discussed directly: how to express its levels in serum. There is considerable confusion on this point, and a fuller understanding of what the concentration units mean will help improve study-to-study comparisons and thereby advance our understanding of the pathobiology of this lipoprotein particle. As discussed here, the term Lp(a) mass refers to the entire mass of the particle: lipids, proteins, and carbohydrates combined. At present, there are no commercially available assays that are completely insensitive to the variability in particle mass, which arises not only from differences in apo(a) isoform mass but also from variations in lipid mass. Because lipoprotein "particle number" (molar concentration) has been found to be superior to component-based metrics (ie, low-density lipoprotein particle vs cholesterol concentrations) for CV disease risk prediction, the development of a mass-insensitive Lp(a) assay should be a high priority.

KW - Apolipoprotein(a)

KW - Laboratory methods

KW - Lipoprotein(a)

KW - Lipoproteins

KW - Particle number

UR - http://www.scopus.com/inward/record.url?scp=84909598302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909598302&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2014.08.003

DO - 10.1016/j.jacl.2014.08.003

M3 - Article

C2 - 25499936

AN - SCOPUS:84909598302

VL - 8

SP - 550

EP - 553

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 6

ER -